Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Capecitabine 16 Paclitaxel 12 Docetaxel 10 Cyclophosphamide 10 Epirubicin 8 Gemcitabine 7 Letrozole 6 Doxorubicin 6 Carboplatin 6 Trastuzumab 5 Vinorelbine 4 Cisplatin 4 pertuzumab 3 exemestane 3 Neoadjuvant Therapy 3 Drug Therapy 3 Ado-Trastuzumab Emtansine 3 AC protocol 3 130-nm albumin-bound paclitaxel 3 apatinib 2 Zoledronic Acid 2 Thiotepa 2 Taxes 2 Tamoxifen 2 Standard of Care 2 Radiosurgery 2 Melatonin 2 Lapatinib 2 Injections 2 Goserelin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Breast Neoplasms × soluble LAG-3 protein, human × Clear all

NCT05747794 2024-12-17

AIPAC-003

Immutep S.A.S.

Phase 2/3 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡